mRNA therapeutics have moved from pandemic response to a broad modality, and their patent landscape is distinctive because the mRNA molecule is patented separately from the lipid nanoparticle that delivers it. This article addresses the construct itself. A therapeutic mRNA is engineered in several parts, and each is a distinct region of patenting: the modified nucleosides, such as pseudouridine variants, that reduce the innate immune response, an insight foundational to making mRNA usable in humans;¹ the five-prime cap that enables translation;² the untranslated regions that tune expression;³ the poly-A tail that stabilizes the molecule and, with the cap, defines the ends that are engineered for therapeutic performance;⁴ the sequence and codon optimization that improves output; and, increasingly, the self-amplifying and trans-amplifying designs that let a smaller dose replicate inside the cell. Rational-design analyses describe the construct as exactly this layered assembly, from cap through untranslated regions and open reading frame to poly-A tail, and the choice of nucleoside modification continues to shape immunogenicity.⁵,⁶ Because these elements can be claimed independently and are often held by different owners, and because delivery adds its own separate estate, freedom-to-operate for an mRNA product is a multi-layer, multi-owner analysis rather than a single clearance.

The field's IP has been defined by landmark disputes, which have raised the stakes across every layer. Foundational modified-nucleoside discoveries originated in academic work and are licensed through a chain of sublicenses, and the leading commercial developers have litigated over who owns and who may use the core construct technologies. Several of these cases have moved through courts in the United States and through the European Patent Office: one developer's settlement arrangements to resolve pending mRNA vaccine litigation with two others were entered on August 7, 2025,⁷ while a series of European construct patents were revoked or narrowed in opposition proceedings, with a further opposed patent maintained in amended form.⁸ The practical result is that a developer can hold a strong position on its own sequence and still face freedom-to-operate exposure on the nucleoside chemistry, the untranslated regions, or the tail, plus the separate delivery layer. This shows in the record: across the Cypris corpus of more than 500 million patents and scientific papers, the mRNA vaccine and therapeutics set holds on the order of 16,694 families and grew from about 582 in 2020 to roughly 2,062 in 2024, with the most active assignees including ModernaTx, Translate Bio, CureVac, the University of Pennsylvania, MIT, and BioNTech, and the United States far ahead of China and Germany on geography; 2025 and 2026 counts are partial because of the publication lag.

The strategic picture turns on where defensible, hard-to-design-around IP sits. The foundational modified-nucleoside and core-structure estates are comparatively crowded and heavily licensed, so the open, high-value ground is increasingly in self-amplifying and trans-amplifying mRNA, in novel nucleoside modifications and sequence-engineering methods, in untranslated-region and structural designs that improve durability and expression, in enzymatic capping and manufacturing methods, and in mRNA applications beyond vaccines.⁷ Self-amplifying mRNA has now reached the market: the first self-amplifying mRNA vaccine, which encodes a replicase alongside the antigen so the molecule copies itself inside the cell, was approved in Japan in 2023 and by the European Commission in February 2025, though not, as of this writing, in the United States.⁹ Circular RNA and other next-generation constructs are a further frontier. Reading the landscape by construct layer and by owner, and tracking both the patents and the underlying RNA-biology research, is what separates a workable position from a blocked one.

What creates FTO risk in mRNA constructs

Modified-nucleoside claims. These cover the chemistries, such as pseudouridine variants, that reduce immune activation, a foundational and heavily licensed layer.¹,⁶

Cap and untranslated-region claims. These cover the five-prime cap and the untranslated regions that enable and tune translation, a distinct expression-control layer.²,³

Poly-A tail and stability claims. These cover the tail and other end-engineering technologies, a separately owned and actively litigated layer.⁴

Sequence and codon-optimization claims. These cover methods to improve protein output from a given sequence, which can carry their own IP.

Self-amplifying and next-generation-construct claims. These cover self-amplifying, trans-amplifying, and circular-RNA designs, an emerging and comparatively open layer.⁹

How AI-powered landscape and FTO analysis helps

A modular, multi-owner, litigation-shaped landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant nucleoside, cap, untranslated-region, tail, and self-amplifying claims regardless of terminology, attribution that resolves academic and commercial owners and the sublicense chains to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and disputes. Because RNA-biology advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the field is heading.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as mRNA therapeutics across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by construct layer, modified nucleoside, cap, untranslated region, poly-A tail, and self-amplifying design, and normalizes academic and commercial owners and their sublicense chains to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list, and can separate the construct estate from the delivery estate. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where new modifications and constructs emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is mRNA construct IP separate from delivery IP? mRNA construct IP is separate from delivery IP because the mRNA molecule and the lipid nanoparticle that carries it are distinct inventions with distinct owners. The construct covers the nucleosides, cap, untranslated regions, tail, and sequence; the delivery covers the lipid formulation. Freedom-to-operate must clear both estates separately.

Why were modified nucleosides so important? Modified nucleosides were important because replacing a natural nucleoside with a modified form, such as a pseudouridine variant, sharply reduced the innate immune response that had previously made mRNA unsuitable as a drug. This breakthrough helped enable therapeutic mRNA. The foundational nucleoside estates are therefore central to the landscape.

What claim types create FTO risk in mRNA constructs? Five claim types create FTO risk: modified-nucleoside claims, cap and untranslated-region claims, poly-A tail and stability claims, sequence and codon-optimization claims, and self-amplifying and next-generation-construct claims. Each covers a distinct layer and can be held by a different owner. The nucleoside and stability layers have been especially contested.

Why has mRNA IP been so heavily litigated? mRNA IP has been heavily litigated because the modality became commercially enormous very quickly, foundational construct technologies are held by a small number of parties, and their scope overlaps. Disputes have run through courts and the European Patent Office, with some resolved by settlement, including arrangements entered in August 2025, and others contested in opposition proceedings. The outcomes shape licensing across the field.

Has a self-amplifying mRNA product been approved? Yes. The first self-amplifying mRNA vaccine, which encodes a replicase so the mRNA copies itself inside cells, was approved in Japan in 2023 and by the European Commission in February 2025. It had not been approved in the United States as of this writing. Self-amplifying designs aim to achieve a given effect at a lower dose.

Where is the white space in mRNA therapeutics? The white space includes self-amplifying and trans-amplifying mRNA, novel nucleoside modifications and sequence engineering, untranslated-region and structural designs, enzymatic capping and manufacturing, circular RNA, and applications beyond vaccines. The foundational construct layers are crowded and licensed. The durable, defensible value is in next-generation constructs and new applications.

What software helps analyze the mRNA therapeutics patent landscape? Software for the mRNA landscape should resolve academic and commercial owners and sublicense chains to canonical entities, separate the construct and delivery estates, cluster the nucleoside, cap, untranslated-region, tail, and self-amplifying layers, search patents and scientific literature semantically, and monitor disputes and new filings continuously. Cypris does this across more than 500 million patents and scientific papers using a proprietary R&D ontology, semantic search, Cypris Q, and Agentic Monitoring.

Which teams need mRNA patent landscape and FTO analysis? mRNA patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at mRNA and vaccine companies, as well as investors assessing mRNA assets. The modular, litigation-shaped landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

Endnotes

1. Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005). Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity, 23(2). https://doi.org/10.1016/j.immuni.2005.06.008
2. Kore, A. R., Senthilvelan, A., & Shanmugasundaram, M. (2022). Recent advances in modified cap analogs for mRNA-based vaccines. The Chemical Record, 22(9). https://doi.org/10.1002/tcr.202200005
3. Zhang, H., et al. (2024). Optimization of the 5′ untranslated region of mRNA vaccines. Scientific Reports, 14. https://doi.org/10.1038/s41598-024-70792-x
4. Jemielity, J., et al. (2023). Chemical modifications of mRNA ends for therapeutic applications. Accounts of Chemical Research, 56(20). https://doi.org/10.1021/acs.accounts.3c00442
5. To, K. K. W., & Cho, W. C. S. (2021). An overview of rational design of mRNA-based therapeutics and vaccines. Expert Opinion on Drug Discovery, 16(11). https://doi.org/10.1080/17460441.2021.1935859
6. Liu, Y. (2026). The impact of nucleotide modifications on the immune responses of mRNA vaccines. https://doi.org/10.54097/bmddk068
7. CureVac N.V. (2025). CureVac announces resolution of patent litigation with Pfizer/BioNTech (Form 6-K, Exhibit 99.1). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1809122/000110465925075352/tm2522930d1_ex99-1.htm
8. CureVac N.V. (2025). CureVac receives positive validity decision from the European Patent Office in litigation against BioNTech SE (Form 6-K, Exhibit 99.1). U.S. Securities and Exchange Commission. https://www.sec.gov/Archives/edgar/data/1809122/000110465925028798/tm2510706d1_ex99-1.htm
9. European Medicines Agency (2024). Kostaive (zapomeran): EPAR public assessment report. https://www.ema.europa.eu/en/documents/assessment-report/kostaive-epar-public-assessment-report_en.pdf

‍

Antibody-drug conjugates are among the most active areas of oncology drug development, and their patent landscape is distinctive because an ADC is a modular product whose components are patented separately. An ADC joins a monoclonal antibody to a cytotoxic payload through a chemical linker, using a defined conjugation chemistry and a specified drug-to-antibody ratio. Each of these elements, the antibody, the linker, the payload, the conjugation site and chemistry, and the ratio, can be claimed independently, so freedom-to-operate risk is layered across several distinct patent families held by different owners. Freedom-to-operate determines whether making, using, or selling a product would infringe another party's active patent claims, and peer-reviewed analysis of ADC intellectual property has long stressed that the assessment must cover every layer, not the molecule as a whole.¹

The landscape has grown intensely. A peer-reviewed update to the ADC patent literature notes that, a decade after the first ADC patent-landscape review, the basic principles still apply but the field has expanded and matured substantially, with next-generation payloads, linkers, and site-specific conjugation driving new filings.² That expansion is visible in the patent record: across the Cypris corpus of more than 500 million patents and scientific papers, ADC-specific patent families more than doubled from about 2,645 in 2018 to about 5,949 in 2024, with 2025 counts partial because of the roughly eighteen-month publication lag. The growth has been propelled by potent topoisomerase-1 payloads such as the deruxtecan and govitecan classes, new linker and site-specific conjugation technologies, and the expansion of ADCs from hematologic cancers into solid tumors. Peer-reviewed patent reviews map the issued patents onto specific linker and payload technologies,³ and document filing activity concentrated among a small set of leading developers, with more than a dozen approved ADCs and a large clinical pipeline behind the trend.⁴ Within the Cypris corpus, conjugation and site-specific chemistry and the linker layer are the most heavily worked parts of the ADC set, consistent with where litigation and FTO risk concentrate.

Litigation has made the stakes concrete, and it has centered on the linker layer. In the multi-year dispute between Seagen and Daiichi Sankyo over the linker technology used in a blockbuster HER2-targeted ADC, a jury had found for Seagen and awarded damages, but on December 2, 2025 the US Court of Appeals for the Federal Circuit reversed, holding Seagen's key linker patent invalid for lack of written description and non-enablement and vacating the damages award.⁵ The court reasoned that the priority disclosure did not convey possession of the specific claimed subgenus of linkers and that a broad functional claim was not enabled.⁵ For developers, the practical lesson is twofold: the linker and conjugation layer is heavily contested and a frequent source of FTO risk, and the proprietary payload estates built around leading platforms, such as the DXd payload, create freedom-to-operate exposure for follow-on and biosimilar ADCs in markets where those estates are in force. That exposure is concentrated: across the Cypris corpus, the most active assignees in the ADC-specific set include Genentech, Seagen, Daiichi Sankyo, Regeneron, Immunomedics, and ImmunoGen, several of which anchor the payload and linker estates most likely to surface in an FTO search. Because applications publish about eighteen months after filing, the newest linker, payload, and conjugation filings are under-represented, so the current frontier is more active than granted-patent counts suggest.

What creates FTO risk in ADCs

Antibody claims. These cover the targeting antibody and its engineering, a distinct layer that can implicate separate antibody IP.

Linker claims. These cover cleavable and non-cleavable linkers and their chemistry, the layer most heavily litigated, as the Seagen v. Daiichi Sankyo dispute demonstrates.⁵

Payload claims. These cover the cytotoxic agent, including proprietary payload estates built around specific classes, which create FTO exposure for follow-on products.

Conjugation and site-specific claims. These cover how payload and antibody are joined and where, an area of intense recent innovation and patenting.³

Drug-to-antibody ratio and formulation claims. These cover the ratio and the finished formulation, adding further independently claimable layers.

How AI-powered landscape and FTO analysis helps

A modular, multi-owner, actively litigated landscape is beyond manual clearance. AI-powered analysis addresses this with semantic search that retrieves relevant antibody, linker, payload, and conjugation claims regardless of terminology, attribution that resolves the many owners to canonical entities, claim-level analysis that separates the layers, and continuous monitoring that tracks new filings and litigation developments. Because ADC advances appear in scientific literature before they are patented, reading both patents and literature gives earlier warning of where the landscape is extending.

Where Cypris fits

Cypris runs patent landscape and freedom-to-operate analysis for modular, contested fields such as antibody-drug conjugates across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters the landscape by layer, antibody, linker, payload, and conjugation, and normalizes owners to canonical entities, so a team sees how rights are distributed across the many parties rather than a flat list. Semantic search across patents and scientific literature surfaces relevant claims regardless of terminology and connects filings to the underlying research, which is where next-generation linkers and payloads emerge first. Cypris Q, the platform's agentic layer, lets teams run landscape and FTO analysis conversationally and chain the attribution, clustering, and claim-level analysis across layers, and Agentic Monitoring tracks the landscape over time and flags new filings and developments as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

Why is freedom-to-operate hard for antibody-drug conjugates? Freedom-to-operate is hard for antibody-drug conjugates because an ADC is a modular product whose antibody, linker, payload, conjugation chemistry, and drug-to-antibody ratio are each independently patentable and often held by different owners. Clearing one layer does not clear the others. FTO must therefore be assessed layer by layer across multiple patent families.

What are the main claim types in the ADC landscape? The main claim types are antibody claims, linker claims, payload claims, conjugation and site-specific claims, and drug-to-antibody-ratio and formulation claims. Each covers a distinct layer of the ADC and can independently create infringement risk. The linker and conjugation layers are especially heavily patented and litigated.

What was the Seagen v. Daiichi Sankyo dispute about? The Seagen v. Daiichi Sankyo dispute concerned linker technology used in a blockbuster HER2-targeted ADC. A jury had found for Seagen and awarded damages, but on December 2, 2025 the US Court of Appeals for the Federal Circuit reversed, holding Seagen's key linker patent invalid for lack of written description and enablement and vacating the award. It illustrates how the linker layer drives ADC freedom-to-operate risk and how even a trial win can be undone on validity grounds.

How fast is ADC patenting growing? ADC patenting has grown rapidly, with ADC-specific patent families more than doubling between 2018 and 2024 in the Cypris corpus. Growth has been driven by potent topoisomerase-1 payloads, new linker and site-specific conjugation technologies, and expansion from hematologic cancers into solid tumors. Because applications publish about eighteen months after filing, recent activity is under-represented.

What is a payload estate and why does it matter for FTO? A payload estate is the set of patents an organization holds around a specific cytotoxic payload class and its use in ADCs. It matters for FTO because a strong payload estate, such as the one around the DXd payload, can create infringement exposure for follow-on and biosimilar ADCs in markets where it is in force. Developers must assess payload IP as a distinct layer.

Why does ADC analysis need scientific literature? ADC analysis needs scientific literature because linker, payload, and conjugation advances appear in research before they are patented, so the literature gives the earliest signal of where the landscape is extending. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams need ADC patent landscape and FTO analysis? ADC patent landscape and FTO analysis is needed by R&D, IP, and business-development teams at pharmaceutical and biotech companies developing ADCs, payloads, linkers, and conjugation platforms, as well as investors assessing ADC assets. The modular, litigated landscape makes structured analysis essential. Cypris serves hundreds of enterprise customers across pharmaceuticals and other research-intensive industries.

How current does an ADC landscape need to be? An ADC landscape needs to be continuously current, because litigation is active, next-generation linker and payload filings publish constantly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track the landscape and flag new filings and developments as they publish.

‍

Battery circularity, the recycling, reuse, and repurposing of batteries, has become the fastest-growing area of battery patenting, and its landscape is a map of the coming competition over critical minerals. According to a joint study by the European Patent Office and the International Energy Agency, international patent families related to battery circularity grew at an average of 42 percent per year from 2017 to 2023, compared with 16 percent for rechargeable battery manufacturing overall and 2 percent across all technical fields.¹ Over the decade the number of these families rose roughly sevenfold.¹ The driver is structural: more than one in four cars sold globally in 2025 was electric, and around 1.2 million electric-vehicle batteries could reach end of life in 2030, rising to 14 million by 2040, so managing and reclaiming that volume is both an environmental necessity and a supply-chain strategy.¹

The landscape is geographically concentrated and shifting quickly. Asian applicants accounted for 63 percent of battery-circularity patent families in 2023, and China's share rose from 5 percent in 2013 to 29 percent in 2023, with Brunp, the recycling subsidiary of a major battery maker, overtaking established Japanese and Korean firms to become the most active filer.¹ European companies and research institutes account for roughly 20 percent of families, with particular strength in the collection and pre-processing of used batteries and in chemical transformation to recover raw materials, reflecting Europe's current role more as a battery user than a producer.¹ An independent count across the Cypris corpus of more than 500 million patents and scientific papers reproduces the same picture: China holds roughly two-thirds of the recycling-specific family set, well ahead of the United States, Germany, South Korea, and Japan, and Brunp is the single most active assignee, ahead of chemical and battery-materials firms such as BASF and Sumitomo Metal Mining. The strategic significance is large: energy storage now represents about 40 percent of all energy-related patenting and is heading toward half, and recycled materials could meet more than a fifth of demand for lithium, nickel, and cobalt by 2040.¹

The technology landscape divides into distinct stages, each a region of patenting. A peer-reviewed patent-network analysis of lithium-ion battery recycling covering 1990 to 2024 finds activity rising steeply since around 2020, with China leading and international collaboration remaining limited,² and bibliometric analysis of the field documents the same long-run acceleration in recycling research and patenting.³ Across the Cypris corpus, hydrometallurgy is the most patented chemical-recovery route, well ahead of pyrometallurgy, while direct recycling and cathode regeneration remain comparatively nascent; a large, separate cluster covers collection, pre-processing, and separation, the earlier stage where Europe is comparatively strong. Metal recovery and cathode regeneration are where much of the chemical innovation and value concentrate, with key work focused on improving leaching efficiency, developing purification methods, and relithiation strategies that restore spent cathode materials. Because applications publish about eighteen months after filing, the most recent activity is under-represented, so the current frontier is even more active than the figures show.

Where the battery-circularity white space is

Direct cathode regeneration. Restoring spent cathode material directly, rather than breaking it down to metals, is a higher-value route that remains comparatively nascent in the patent record, leaving room for defensible positions.²

Efficient metal recovery. Improving leaching efficiency and purification for lithium, nickel, and cobalt is where much chemical innovation concentrates and where recovery economics are decided.²

Collection and pre-processing. Sorting, dismantling, and safe handling, including remote-handling technologies, are an earlier stage where activity is comparatively less crowded and where European applicants are relatively strong.¹

Reuse and repurposing. Second-life applications for batteries, distinct from material recovery, are a separate and growing layer.

Design for recyclability. Battery designs that ease disassembly and recovery link circularity back to manufacturing and are an emerging cross-over area.

How AI-powered landscape and white space analysis helps

Resolving a fast-growing landscape across stages, chemistries, and geographies requires more than keyword search. AI-powered analysis addresses this with semantic search that clusters activity by recovery route and processing stage across varied terminology, attribution that normalizes filers to canonical entities and tracks shifting leadership, and continuous monitoring that keeps pace with a field growing far faster than average. Because circularity advances appear in scientific literature before they are patented, reading both patents and literature gives the earliest signal of where the frontier is moving.

Where Cypris fits

Cypris runs patent landscape and white space analysis for fast-growing energy fields such as battery circularity across a corpus of more than 500 million patents and scientific papers, organized through a proprietary R&D ontology. The ontology clusters activity by recovery route, hydrometallurgy, direct regeneration, separation, and pyrometallurgy, and by processing stage, and normalizes filers to canonical entities, so a team can resolve which routes and stages are crowded and which remain open as white space, and can track shifting leadership as new entrants rise. Semantic search across patents and scientific literature connects filings to the underlying materials and process research, which is where circularity advances appear first. Cypris Q, the platform's agentic layer, lets teams run landscape and white space analysis conversationally and chain the clustering, attribution, and gap analysis, and Agentic Monitoring tracks a defined route over time and flags new patents and papers as they publish. Cypris provides enterprise API partnerships with OpenAI, Anthropic, and Google, and is built with enterprise-grade security. Cypris serves hundreds of enterprise customers across pharmaceuticals, chemicals, advanced materials, energy, and other regulated industries.

FAQ

How fast is battery-recycling patenting growing? Battery-recycling patenting is growing very fast. According to the EPO and IEA, international patent families in battery circularity grew at an average of 42 percent per year from 2017 to 2023, versus 16 percent for battery manufacturing and 2 percent across all technical fields, roughly a sevenfold increase over the decade. It is now growing faster than battery patenting in general.

Who leads in battery-circularity patents? Asian applicants held 63 percent of battery-circularity patent families in 2023. China's share rose from 5 percent in 2013 to 29 percent in 2023, and Brunp, a major battery maker's recycling subsidiary, overtook established Japanese and Korean firms as the most active filer. European companies and research institutes hold roughly 20 percent, with strength in collection and pre-processing. An independent Cypris-corpus count reproduces China's roughly two-thirds share and Brunp's lead.

What technologies does the battery-recycling landscape cover? The battery-recycling landscape covers collection, sorting, and dismantling; mechanical processing; and metal recovery and cathode regeneration. Analysis of the patent record finds hydrometallurgy the most patented chemical-recovery route, ahead of pyrometallurgy, with direct recycling still comparatively nascent. Innovation concentrates on leaching efficiency, purification, and relithiation.

Why is battery circularity strategically important? Battery circularity is strategically important because it is a secondary supply of critical minerals. Around 1.2 million electric-vehicle batteries could reach end of life in 2030 and 14 million by 2040, and recycled materials could meet more than a fifth of lithium, nickel, and cobalt demand by 2040. This links recycling to supply-chain security and energy security.

Where is the white space in battery recycling? The white space in battery recycling includes direct cathode regeneration, efficient metal recovery and purification, collection and pre-processing including remote handling, reuse and repurposing for second-life applications, and design for recyclability. Metal recovery and cathode regeneration are where chemical innovation concentrates. The higher-value opportunities are in routes that improve recovery economics.

Why does battery-recycling analysis need scientific literature? Battery-recycling analysis needs scientific literature because process and materials advances appear in research before they are patented, so the literature gives the earliest signal. Analyzing patents alone gives a lagging view. Cypris analyzes both across more than 500 million patents and scientific papers.

Which teams use battery-recycling patent landscape analysis? Battery-recycling patent landscape analysis is used by R&D, innovation, IP, and strategy teams at battery makers, recyclers, automotive and energy companies, materials developers, and their partners, as well as investors and policymakers. It informs where to invest, where to file, and where competitors are concentrated. Cypris serves hundreds of enterprise customers across energy, advanced materials, chemicals, and other regulated industries.

How do you keep a battery-recycling landscape current? Keeping a battery-recycling landscape current requires continuous monitoring, because the field is growing far faster than average, leadership is shifting quickly, and publication lag hides the most recent activity. A one-time landscape ages quickly. Cypris uses Agentic Monitoring to track a defined route and flag new patents and papers as they publish.

Endnotes

1. International Energy Agency & European Patent Office (2026). Battery circularity: innovation trends for a future source of critical materials. IEA, Paris. https://www.iea.org/reports/battery-circularity
2. von Delft, S., Schlehuber, S., & Hemmelder, A. (2025). Uncovering collaboration and knowledge areas in lithium-ion battery recycling. EES Batteries. https://doi.org/10.1039/d5eb00056d
3. Li, Y., Guo, Y., Guan, J., Zhang, X., & Lou, X. (2022). Global trend for waste lithium-ion battery recycling from 1984 to 2021: a bibliometric analysis. Minerals, 12(12), 1514. https://doi.org/10.3390/min12121514

‍